WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC50 (DC50>1 µM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4[1].
Molekulargewicht:
873.96
CAS Nummer:
[2869057-11-2]
Formel:
C45H51N11O8
Target-Kategorie:
Epigenetic Reader Domain
Anwendungsbeschreibung:
Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
